Atara CEO Pascal Touchon to step down, succeeded by Cokey Nguyen; Q2 net loss narrows to $19M

Atara Biotherapeutics, Inc.

Pascal Touchon steps down as CEO effective Sep 9, 2024, becomes Chairman; Cokey Nguyen promoted to President and CEO.
Q2 2024 net loss of $19.0M ($3.10 per share) vs $71.1M loss in Q2 2023; revenue of $28.6M (up from $1.0M).
Tab-cel BLA accepted with Priority Review, PDUFA target Jan 15, 2025; $20M milestone received from Pierre Fabre.
Cash, equivalents, short-term investments $35.3M; with milestones and inventory purchase total liquidity $73.2M; cash runway into 2027.
ATA3219 NHL study enrolling with initial data expected Q1 2025; LN study initiation Q4 2024, data mid-2025.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Pascal Touchon

President and Chief Executive Officer

ATRA · Atara Biotherapeutics, Inc.

Effective: 2024-09-09
Successor: AnhCo Nguyen
Filed: August 12, 2024, 7:59 PM ET

On August 10, 2024, Pascal Touchon notified the Board of Directors (the “Board”) of the Company of his decision to step down as the Company’s President and Chief Executive Officer, effective as of September 9, 2024

Appointed

Pascal Touchon

Chairman of the Board

ATRA · Atara Biotherapeutics, Inc.

Effective: 2024-09-09
Filed: August 12, 2024, 7:59 PM ET

Effective as of the Separation Date, Dr. Touchon will be appointed as Chairman of the Board and will remain a member of the Board.

Appointed

AnhCo Nguyen

President and Chief Executive Officer

ATRA · Atara Biotherapeutics, Inc.

Effective: 2024-09-09
Filed: August 12, 2024, 7:59 PM ET

On August 10, 2024, the Board appointed AnhCo Nguyen, Ph.D. as the Company’s President and Chief Executive Officer and a member of the Board, effective September 9, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Pascal Touchon departed as President and Chief Executive Officer at Atara Biotherapeutics, Inc..

Action: stepped down
Role: President and Chief Executive Officer

Exact text from the filing

On August 10, 2024, Pascal Touchon notified the Board of Directors (the “Board”) of the Company of his decision to step down as the Company’s President and Chief Executive Officer, effective as of September 9, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Pascal Touchon was appointed as Chairman of the Board at Atara Biotherapeutics, Inc..

Action: appointed
Role: Chairman of the Board

Exact text from the filing

Effective as of the Separation Date, Dr. Touchon will be appointed as Chairman of the Board and will remain a member of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

AnhCo Nguyen was appointed as President and Chief Executive Officer at Atara Biotherapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On August 10, 2024, the Board appointed AnhCo Nguyen, Ph.D. as the Company’s President and Chief Executive Officer and a member of the Board, effective September 9, 2024

View on SEC.gov

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-095526

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.